Revolutionizing Cancer Diagnosis: Immunovia AB Secures Funding to Accelerate Development of Innovative Blood Tests

Immunovia AB, a pioneering diagnostic company focused on revolutionizing the early detection of cancer and autoimmune diseases, has announced a significant funding milestone that will bolster its innovative research and development endeavors. Although the specific amount raised has yet to be disclosed, this new capital injection is expected to advance the commercialization of its proprietary IMMray™ test platform, which utilizes state-of-the-art antibody biomarker microarray analysis and machine learning technology. Founded in 2007, Immunovia emerged from groundbreaking research conducted at Lund University's Department of Immuntechnology and the CREATE Health Cancer Center, aiming to establish highly accurate blood tests that can identify disease-specific biomarker signatures. The company’s flagship product, IMMray™ PanCan-d, holds promise as the world’s first blood-based test dedicated to the early detection of pancreatic cancer and is currently undergoing extensive clinical evaluations in major trials, including PanFAM-1, PanSYM-1, and PanDIA-1. With the establishment of Immunovia, Inc. in Marlborough, Massachusetts, the company is well-positioned to expand its impact in the U.S. market. The newly acquired funds will be pivotal in accelerating clinical development and bringing their innovative diagnostic solutions closer to those in need. Immunovia's shares are listed on Nasdaq Stockholm under the ticker IMMNOV, and the company remains committed to its mission of advancing early detection methodologies to save lives. For more information about Immunovia and its groundbreaking technologies, please visit www.immunovia.com.